INSYS Therapeutics shareholders have an opportunity to recover their investment losses.
Click "Join this Class Action" above.
INSYS Therapeutics, Inc.
Rosen Law Firm announces the filing of a securities class action lawsuit on behalf of purchasers of INSYS Therapeutics, Inc. securities (NASDAQ: INSY) from March 3, 2015 through January 25, 2016, all dates inclusive (the “Class Period”), resulting from allegations that INSYS Therapeutics may have issued materially misleading business information to the investing public.
If you purchased shares of INSYS Therapeutics from March 3, 2015 through January 25, 2016 and would like to join the action, please click "Join This Class Action" above.
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against INSYS Therapeutics, Inc. – INSY
New York, N.Y., February 9, 2016. Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of INSYS Therapeutics, Inc. securities (NASDAQ: INSY) from March 3, 2015 through January 25, 2016, all dates inclusive (the “Class Period”). The lawsuit seeks to recover damages for INSYS Therapeutics investors under the federal securities laws.
To join the INSYS Therapeutics class action, go to the firm’s website at http://rosenlegal.com/cases-834.html or call Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via email at email@example.com or firstname.lastname@example.org.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, Defendants throughout the Class Period issued materially false and misleading statements to investors and/or failed to disclose that: (1) INSYS Therapeutics was engaged in the illegal and improper off-labeling marketing of Subsys; (2) certain INSYS Therapeutics employees were complicit in an illegal kickback scheme operated for the purpose of increasing prescriptions of Subsys; and (3) as a result, INSYS Therapeutics’ financial statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 4, 2016. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to the firm’s website at http://rosenlegal.com/cases-834.html for more information. You may also contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via email at email@example.com or firstname.lastname@example.org.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Laurence Rosen, Esq.
Phillip Kim, Esq.
Kevin Chan, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 34th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827